Zobrazeno 1 - 5
of 5
pro vyhledávání: '"M. R. Mukhitova"'
Autor:
E. V. Borodavina, S. I. Kutukova, A. Yu. Shurinov, E. B. Vasil’eva, A. O. Guz, I. V. Grishkevich, S. D. Karateeva, A. R. Shakhmatova, R. S. Slobodyanskiy, O. V. Romanchuk, M. R. Mukhitova, M. P. Karpovich, S. P. Dmitriev, O. S. Saypeeva, K. A. Tolpeykina, S. S. Tolstov, A. V. Makarova, Ya. A. Tyugina, E. G. Ovchinnikova
Publikováno v:
Опухоли головы и шеи, Vol 14, Iss 2, Pp 98-107 (2024)
Differentiated thyroid cancer is one of the most common malignant diseases of the endocrine system. Usually, it responds well to the standard treatment (surgery + radioiodine therapy), especially at early stages. During both treatment and dynamic obs
Externí odkaz:
https://doaj.org/article/2707608dd266460cbd4fca8974d071d9
Autor:
V. V. Petkau, A. V. Sultanbaev, K. V. Menshikov, A. S. Antipin, M. V. Volkonsky, V. M. Filippova, Yu. V. Vasilyeva, A. A. Tarkhanov, M. R. Mukhitova, M. Zh. Murzalina, A. R. Safarova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 32, Iss 4, Pp 75-88 (2022)
Aim. To determine lenvatinib treatment outcomes in patients with advanced unresectable hepatocellular carcinoma (uHCC) in real clinical practice.Patients and methods. A multicenter retrospective observational study included 58 patients with a confirm
Externí odkaz:
https://doaj.org/article/63c0b6ac5e87423bbeab0b4c7ffae672
Autor:
E. V. Borodavina, P. A. Isaev, A. Yu. Shurinov, P. O. Rumyantsev, V. V. Krylov, K. M. Petrosyan, A. D. Kaprin, S. A. Ivanov, S. O. Podvyaznikov, I. S. Romanov, A. M. Mudunov, K. Yu. Slashchuk, R. S. Zhikhorev, M. V. Volkonsky, R. M. Chagova, I. R. Suslova, A. I. Khryapa, A. Kh. Lepshokova, N. L. Fadeeva, A. R. Safarova, L. P. Kaleykina, E. V. Lymar, E. M. Chernyakova, O. A. Snezhko, A. E. Zinkovskaya, F. F. Mufazalov, E. S. Kuzmina, Yu. V. Druzhinina, Sh. I. Musin, M. R. Mukhitova, A. I. Khasanova, S. Z. Safina, S. L. Kirienko
Publikováno v:
Опухоли головы и шеи, Vol 10, Iss 1, Pp 65-72 (2020)
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these p
Externí odkaz:
https://doaj.org/article/90b3f88358a64191b3df59c14333279c
Autor:
M. I. Volkova, A. S. Kalpinskiy, P. S. Borisov, O. I. Evsyukova, A. S. Olshanskaya, V. B. Matveev, B. Ya. Alekseev, E. V. Peganova, A. F. Nasretdinov, E. V. Lymar, E. G. Ovchinnikova, T. A. Sveklina, E. A. Usynin, A. M. Abdelgafur, E. A. Tararova, L. M. Shumova, A. S. Belenkov, I. Yu. Dolgov, N. G. Ponomareva, I. V. Evstigneeva, A. N. Ivanov, A. R. Isaev, R. V. Leonenkov, A. V. Meskikh, M. R. Mukhitova, S. A. Orlova, I. V. Teslenok, M. M. Shegurova, M. T. Aivazov, Z. V. Amoev, K. G. Babina, A. A. Vorontsova, E. V. Karabina, N. V. Kirdakova, I. E. Shumskaya, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, E. S. Lyutova, M. M. Fael, A. N Chugarova, A. S. Antipin
Publikováno v:
Onkourologiâ, Vol 17, Iss 1, Pp 31-44 (2021)
Objective. The primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate and duration, tumor control rate and duration, as well as safety profile of lenvatinib with everolimus in consecutiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91177b36520353fff8907e4b001ccdd
https://doi.org/10.17650/1726-9776-2021-17-1-31-44
https://doi.org/10.17650/1726-9776-2021-17-1-31-44
Autor:
A. I. Khryapa, E. M. Chernyakova, F. F. Mufazalov, E. V. Lymar, S. A. Ivanov, K. Yu. Slashchuk, N. L. Fadeeva, R. M. Chagova, V. V. Krylov, A. R. Safarova, A. M. Mudunov, S. Z. Safina, M. R. Mukhitova, A. I. Khasanova, S. O. Podvyaznikov, K. M. Petrosyan, I. R. Suslova, R. S. Zhikhorev, A. Kh. Lepshokova, P. A. Isaev, S. L. Kirienko, Yu. V. Druzhinina, I. S. Romanov, E. S. Kuzmina, Andrey Kaprin, Sh. I. Musin, O. A. Snezhko, A. Yu. Shurinov, L. P. Kaleykina, A. E. Zinkovskaya, Pavel O. Rumyantsev, M. V. Volkonsky, E. V. Borodavina
Publikováno v:
Opuholi Golovy i Šei, Vol 10, Iss 1, Pp 65-72 (2020)
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a048aaf0f080825f30978d7d8770c6d6
https://ogsh.abvpress.ru/jour/article/view/478
https://ogsh.abvpress.ru/jour/article/view/478